Recent clinical trials confirm the benefits of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of 100 mg/dL, with modifications for very high risk and moderately high-risk individuals.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

High-intensity statin therapy is recommended for people with diabetes and established atherosclerotic cardiovascular disease, with a goal of 70 mg/dL LDL-C target.

The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA* Guidelines on the Management of Blood Cholesterol in Diabetes

The updated NCEP Adult Treatment Panel III guidelines suggest focusing on diet, exercise, and weight control, with statins as first-line drugs for reducing coronary artery disease risk in moderate to high risk patients.

Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.

The new cholesterol treatment guidelines have been controversial, with some arguing they are not evidence-based, but they may significantly impact clinical practice in lipid management.

A pragmatic view of the new cholesterol treatment guidelines.

The 2021 Canadian Cardiovascular Society guidelines continue to recommend statin therapy for patients with atherosclerosis, chronic kidney disease, and low-density lipoprotein cholesterol, while emphasizing risk assessment and lipid evaluation for optimal clinical decision-making.

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.

This paper provides recommendations for patient-centered management of dyslipidemia, focusing on lifestyle therapies, special considerations, and team-based care, to reduce atherosclerotic cardiovascular disease risk.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

Reducing atherogenic cholesterol through lifestyle and drug therapies can lower atherosclerotic cardiovascular disease risk, with statin treatment being the primary modality for reducing risk.

National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.

Recent clinical trials confirm the benefits of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of 100 mg/dL, with modifications for high-risk individuals and those with lifestyle-related risk factors.

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

In 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) transitioned their recommendations for lipid management from an approach focused on “titration to goal low-density lipid cholesterol (LDL-C) level” to a “risk-based approach” ([1][1]). Following the

Trends in Lipid, Lipoproteins, and Statin Use Among U.S. Adults: Impact of 2013 Cholesterol Guidelines.

The updated 2018 ACC/AHA and 2019 ESC/EAS cholesterol management guidelines emphasize refining cardiovascular disease risk estimation and aggressively lowering LDL-C with statin and non-statin agents to prevent cardiovascular disease.

New Recommendations and Revised Concepts in Recent Guidelines on the Management of Dyslipidemias to Prevent Cardiovascular Disease: the 2018 ACC/AHA and 2019 ESC/EAS Guidelines

New cholesterol management guidelines recommend heart healthy lifestyle modifications and statin therapy for individuals at high risk for atherosclerotic cardiovascular disease, potentially benefiting one in three adults in the United States.

Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol

Adhering to these diet and lifestyle recommendations can significantly reduce the risk of developing cardiovascular disease in the US.

Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee

Mediterranean, vegetarian, and vegan diets can help lower lipid profile and reduce the risk of cardiovascular diseases.

Mediterranean, vegetarian and vegan diets as practical outtakes of EAS and ACC/AHA recommendations for lowering lipid profile.

Dietary cholesterol restriction should be reconsidered, as current evidence shows it is not linked to increased risk of coronary heart disease.

Rethinking dietary cholesterol

Adhering to the 2006 AHA Diet and Lifestyle Recommendations can significantly reduce the risk of developing cardiovascular disease.

Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006

Dietary cholesterol guidance should focus on healthy dietary patterns, rather than specific dietary cholesterol targets, as these are more likely to improve diet quality and promote cardiovascular health.

Dietary Cholesterol and Cardiovascular Risk: A Science Advisory From the American Heart Association

A low carbohydrate diet may be beneficial for familial hypercholesterolaemia individuals with insulin resistance or hypercoagulation risk, but further clinical trials are needed to confirm its effectiveness.

Dietary Recommendations for Familial Hypercholesterolaemia: an Evidence-Free Zone

Dietary cholesterol does not play a role in cardiovascular disease development, but eggs and shrimp are high in cholesterol and saturated fatty acids, making them a healthy addition to a balanced diet.

Dietary Cholesterol and the Lack of Evidence in Cardiovascular Disease

Lifestyle modifications, including aerobic exercise, weight reduction, alcohol consumption, and a reduced salt intake, can effectively prevent and manage high blood pressure.

The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension.

What are the latest recommendations for managing cholesterol?

These studies suggest that the latest recommendations for managing cholesterol include a combination of lifestyle changes, high-intensity statin therapy, and a focus on risk-based approaches to aggressively lower LDL-C levels, particularly in high-risk patients.